Cargando…

External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry

INTRODUCTION: Contemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk status with most remaining intermediate risk. Our aim was to validate a four-stratum risk assessment approach cat...

Descripción completa

Detalles Bibliográficos
Autores principales: Boucly, Athénaïs, Weatherald, Jason, Savale, Laurent, de Groote, Pascal, Cottin, Vincent, Prévot, Grégoire, Chaouat, Ari, Picard, François, Horeau-Langlard, Delphine, Bourdin, Arnaud, Jutant, Etienne-Marie, Beurnier, Antoine, Jevnikar, Mitja, Jaïs, Xavier, Simonneau, Gérald, Montani, David, Sitbon, Olivier, Humbert, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245192/
https://www.ncbi.nlm.nih.gov/pubmed/34737227
http://dx.doi.org/10.1183/13993003.02419-2021
_version_ 1784738694444351488
author Boucly, Athénaïs
Weatherald, Jason
Savale, Laurent
de Groote, Pascal
Cottin, Vincent
Prévot, Grégoire
Chaouat, Ari
Picard, François
Horeau-Langlard, Delphine
Bourdin, Arnaud
Jutant, Etienne-Marie
Beurnier, Antoine
Jevnikar, Mitja
Jaïs, Xavier
Simonneau, Gérald
Montani, David
Sitbon, Olivier
Humbert, Marc
author_facet Boucly, Athénaïs
Weatherald, Jason
Savale, Laurent
de Groote, Pascal
Cottin, Vincent
Prévot, Grégoire
Chaouat, Ari
Picard, François
Horeau-Langlard, Delphine
Bourdin, Arnaud
Jutant, Etienne-Marie
Beurnier, Antoine
Jevnikar, Mitja
Jaïs, Xavier
Simonneau, Gérald
Montani, David
Sitbon, Olivier
Humbert, Marc
author_sort Boucly, Athénaïs
collection PubMed
description INTRODUCTION: Contemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk status with most remaining intermediate risk. Our aim was to validate a four-stratum risk assessment approach categorising patients as low, intermediate-low, intermediate-high or high risk, as proposed by the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) investigators. METHODS: We evaluated incident patients from the French PAH Registry and applied a four-stratum risk method at baseline and at first reassessment. We applied refined cut-points for three variables: World Health Organization functional class, 6-min walk distance and N-terminal pro-brain natriuretic peptide. We used Kaplan–Meier survival analyses and Cox proportional hazards regression to assess survival according to three-stratum and four-stratum risk approaches. RESULTS: At baseline (n=2879), the four-stratum approach identified four distinct risk groups and performed slightly better than a three-stratum method for predicting mortality. Four-stratum model discrimination was significantly higher than the three-stratum method when applied during follow-up and refined risk categories among subgroups with idiopathic PAH, connective tissue disease-associated PAH, congenital heart disease and portopulmonary hypertension. Using the four-stratum approach, 53% of patients changed risk category from baseline compared to 39% of patients when applying the three-stratum approach. Those who achieved or maintained a low risk status had the best survival, whereas there were more nuanced differences in survival for patients who were intermediate-low and intermediate-high risk. CONCLUSIONS: The four-stratum risk assessment method refined risk prediction, especially within the intermediate risk category of patients, performed better at predicting survival and was more sensitive to change than the three-stratum approach.
format Online
Article
Text
id pubmed-9245192
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-92451922022-07-01 External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry Boucly, Athénaïs Weatherald, Jason Savale, Laurent de Groote, Pascal Cottin, Vincent Prévot, Grégoire Chaouat, Ari Picard, François Horeau-Langlard, Delphine Bourdin, Arnaud Jutant, Etienne-Marie Beurnier, Antoine Jevnikar, Mitja Jaïs, Xavier Simonneau, Gérald Montani, David Sitbon, Olivier Humbert, Marc Eur Respir J Original Research Articles INTRODUCTION: Contemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk status with most remaining intermediate risk. Our aim was to validate a four-stratum risk assessment approach categorising patients as low, intermediate-low, intermediate-high or high risk, as proposed by the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) investigators. METHODS: We evaluated incident patients from the French PAH Registry and applied a four-stratum risk method at baseline and at first reassessment. We applied refined cut-points for three variables: World Health Organization functional class, 6-min walk distance and N-terminal pro-brain natriuretic peptide. We used Kaplan–Meier survival analyses and Cox proportional hazards regression to assess survival according to three-stratum and four-stratum risk approaches. RESULTS: At baseline (n=2879), the four-stratum approach identified four distinct risk groups and performed slightly better than a three-stratum method for predicting mortality. Four-stratum model discrimination was significantly higher than the three-stratum method when applied during follow-up and refined risk categories among subgroups with idiopathic PAH, connective tissue disease-associated PAH, congenital heart disease and portopulmonary hypertension. Using the four-stratum approach, 53% of patients changed risk category from baseline compared to 39% of patients when applying the three-stratum approach. Those who achieved or maintained a low risk status had the best survival, whereas there were more nuanced differences in survival for patients who were intermediate-low and intermediate-high risk. CONCLUSIONS: The four-stratum risk assessment method refined risk prediction, especially within the intermediate risk category of patients, performed better at predicting survival and was more sensitive to change than the three-stratum approach. European Respiratory Society 2022-06-30 /pmc/articles/PMC9245192/ /pubmed/34737227 http://dx.doi.org/10.1183/13993003.02419-2021 Text en Copyright ©The authors 2022. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Original Research Articles
Boucly, Athénaïs
Weatherald, Jason
Savale, Laurent
de Groote, Pascal
Cottin, Vincent
Prévot, Grégoire
Chaouat, Ari
Picard, François
Horeau-Langlard, Delphine
Bourdin, Arnaud
Jutant, Etienne-Marie
Beurnier, Antoine
Jevnikar, Mitja
Jaïs, Xavier
Simonneau, Gérald
Montani, David
Sitbon, Olivier
Humbert, Marc
External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry
title External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry
title_full External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry
title_fullStr External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry
title_full_unstemmed External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry
title_short External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry
title_sort external validation of a refined four-stratum risk assessment score from the french pulmonary hypertension registry
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245192/
https://www.ncbi.nlm.nih.gov/pubmed/34737227
http://dx.doi.org/10.1183/13993003.02419-2021
work_keys_str_mv AT bouclyathenais externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry
AT weatheraldjason externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry
AT savalelaurent externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry
AT degrootepascal externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry
AT cottinvincent externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry
AT prevotgregoire externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry
AT chaouatari externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry
AT picardfrancois externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry
AT horeaulanglarddelphine externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry
AT bourdinarnaud externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry
AT jutantetiennemarie externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry
AT beurnierantoine externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry
AT jevnikarmitja externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry
AT jaisxavier externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry
AT simonneaugerald externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry
AT montanidavid externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry
AT sitbonolivier externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry
AT humbertmarc externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry